Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13

Core Insights - Windward Bio AG has announced a licensing agreement with Qyuns Therapeutics for the development and commercialization of WIN027, a bispecific antibody targeting TSLP and IL-13, which is expected to enhance treatment for advanced immunological diseases [1][2][3] Group 1: Licensing Agreement Details - The agreement grants Windward Bio exclusive rights to develop, manufacture, and commercialize WIN027 outside of China, with a total deal value of up to $700 million, including upfront payments, equity, and milestone payments contingent on specific achievements [2] - The licensing deal is part of Windward Bio's strategy to expand its immunology pipeline and accelerate the development of differentiated therapies for serious immunological diseases [3] Group 2: Product Information - WIN027 is a humanized IgG1 bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, designed for long-acting inhibition and less frequent dosing, targeting conditions such as asthma, COPD, and atopic dermatitis [4][7] - WIN378, another product in Windward Bio's pipeline, is a long-acting anti-TSLP monoclonal antibody currently in Phase 2 trials for asthma, with initial data expected in 2026 [3][5] Group 3: Market Opportunity - The combined market opportunity for WIN027 and WIN378 is estimated to exceed $50 billion, addressing significant unmet needs across a range of immunological diseases [3]